Available from: Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
*Correspondence: Mario Rotondi, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Review the sources used below for this article: This article references information from the KFF (Kaiser Family Foundation) Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford This article references information from the FDA: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems, Specifically in Adults with Obesity or Overweight This article references information from a recent study published in The New England Journal of Medicine : Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity This article references information from the American College of Cardiology: OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC Versions This article references information from Reuters: Lilly will have supply of new weight loss pill for many countries, exec says

The effect of water temperature and voluntary drinking on the post rehydration sweating
Quick Answer: GLP-1 receptor agonists are contraindicated only in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), not other thyroid cancer types
Medicare Coverage of GLP-1 Drugs